This post was originally published on this site Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. The companies plan to file an investigational new drug application for HPN217 with the U.S. Food and Drug…
Category: <span>Cancer</span>
Firdapse and Ruzurgi are Safe and Effective Options to Treat LEMS, Review Finds
This post was originally published on this site Treatment with Firdapse (Amifampridine phosphate) or Ruzurgi (3,4‐diaminopyridine, or 3,4‐DAP) is effective and well-tolerated among people with Lambert-Eaton myasthenic syndrome (LEMS), even in the presence of immunosuppressants or other medications that alter the responsiveness of the immune system, a review has found. The review study, “Amifampridine tablets…
Tips for Managing Stress When You Have LEMS
This post was originally published on this site Living with a chronic disease like Lambert-Eaton myasthenic syndrome (LEMS) can be very stressful. You may feel like you’ve lost control over your life after being diagnosed. Here are some tips to help reduce stress, and improve your mental and physical health. Get enough sleep It’s easy…
Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers
This post was originally published on this site Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. The request was submitted to the U.S. Food and Drug Administration (FDA), and the company also intends to…
‘LEMme Tell Ya’ Patient Stories in Their Own Words: Will Schuller
This post was originally published on this site Five years ago, Will Schuller was thoroughly enjoying his senior year in high school when he began experiencing symptoms of Lambert-Eaton myasthenic syndrome (LEMS). He was in the marching band, running 25 miles a week, and taking four Advanced Placement classes and one honors class when his…
Will LEMS Affect my Life Expectancy?
This post was originally published on this site Learning you have a rare disorder like Lambert-Eaton myasthenic syndrome (LEMS) can be frightening. Among the first questions many people have is: How will my lifespan be affected? The answer often isn’t clear-cut. What is life expectancy? Life expectancy is an estimate of how long people will live. That…
FDA Approves Calquence as Treatment Option for Adults with CLL and SLL
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was based on promising interim results from two ongoing Phase 3 clinical trials, the ELEVATE-TN (NCT02475681) and ASCEND (NCT02970318)…
I’ve Got the Fire in My Soul
This post was originally published on this site Spontaneity is what I miss most about my pre-LEMS life. No longer can I hop in the car and go to a concert, the beach, or a quick weekend away without planning around meds and treatment schedules. Even with the best-laid plans, I find myself pulling over…
BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US
This post was originally published on this site Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in the U.S to treat people with multiple myeloma and other types of cancer. This follows the decision by the U.S. Food and Drug Administration (FDA) to approve STI Pharma‘s abbreviated new drug application — specific…
Acthar Gel May Improve Sarcoidosis Symptoms, Real-world Study Shows
This post was originally published on this site Acthar Gel (repository corticotropin injection, or RCI) can improve sarcoidosis symptoms, a real-world study shows. Titled “Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records,” the study was published in the journal Therapeutic Advances in Respiratory Disease. Acthar Gel, marketed by Mallinckrodt Pharmaceuticals,…









